Nineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of the 2017 Best Places to Work in Rhode Island, we are the go-to company for Immunogenicity Screening, we are considered founding members of the “gene-to-vaccine” movement towards epitope-driven vaccines, and our team recently celebrated our first commercial license for the Tregitope platform.
The EpiVax logo has changed a few times over the years, and today we are proud to unveil the latest evolution. Check it out:
There are other surprises in store for EpiVax which will be announced soon, so stay tuned!